Neovii Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $50M

Overview

Neovii Biotech is a private, commercial-stage biopharmaceutical company specializing in polyclonal antibody therapies for immunosuppression in transplantation and oncology. The company has an established commercial product, Grafalon®, and is led by an experienced management team with backgrounds from major pharmaceutical firms like Roche, Novartis, and Pfizer. Neovii operates with a fully integrated model spanning research, development, and manufacturing, targeting niche but critical areas within the global transplant and hematology markets.

Organ TransplantationHematology/Oncology

Technology Platform

Polyclonal antibody therapy platform for immunosuppression, targeting multiple antigens to modulate the immune system in transplantation and oncology.

Funding History

2

Total raised:$50M

Series C$45MUndisclosedSep 15, 2020

Grant$5MEuropean UnionJun 15, 2018

Opportunities

Opportunities include expanding the label of its flagship product Grafalon® into new indications within hematology/oncology, such as graft-versus-host disease, and geographic expansion into new markets.

The company's deep expertise in polyclonal antibodies could also be leveraged to develop next-generation immunosuppressive therapies or explore applications in other autoimmune conditions.

Risk Factors

Key risks include high dependence on a single commercial product (Grafalon®), exposing the company to competition from newer immunosuppressive agents and potential generic/biosimilar entry.

The niche focus on transplantation and related oncology limits total market size, and the lack of a visible deep pipeline raises questions about long-term growth beyond the current product.

Competitive Landscape

Neovii competes in the immunosuppressant market with large pharmaceutical companies like Novartis (Simulect), Astellas (Prograf), and Pfizer, as well as with other biologic players developing monoclonal antibodies. Its polyclonal antibody approach occupies a specific niche, competing on efficacy and established use in transplant protocols against both older generics and newer, more targeted agents.

More companies in Biologics / Biosimilars →More companies in Germany →